<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Recent studies suggest that patients on mammalian target of <z:chebi fb="0" ids="9168">rapamycin</z:chebi> (mTOR) inhibitors experience a reduction in cutaneous <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e> by an estimated 50% or more compared with calcineurin inhibitors </plain></SENT>
<SENT sid="1" pm="."><plain>While randomized trials are running, organ transplant recipients are frequently switched from calcineurin inhibitors to mTOR inhibitors when cutaneous <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e> increases </plain></SENT>
<SENT sid="2" pm="."><plain>OBJECTIVES: To slow <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e> in our patient, a heart transplant recipient with a neuropathic <z:e sem="disease" ids="C0206172" disease_type="Disease or Syndrome" abbrv="">diabetic foot</z:e> syndrome who had developed cutaneous <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e> at a rate of more than 20 <z:hpo ids='HP_0002860'>squamous cell carcinomas</z:hpo> (<z:mp ids='MP_0004207'>SCC</z:mp>) annually </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: The patient's immunosuppression was switched from the calcineurin inhibitor <z:chebi fb="0" ids="4031">ciclosporin</z:chebi> to the mTOR inhibitor everolimus </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">Carcinogenesis</z:e> slowed to six <z:mp ids='MP_0004207'>SCC</z:mp> annually; however, he developed recalcitrant <z:e sem="disease" ids="C0206172" disease_type="Disease or Syndrome" abbrv="">diabetic foot</z:e> <z:mpath ids='MPATH_579'>ulcers</z:mpath> which were purely neuropathic and nonangiopathic, and a limb-threatening fistulating necrotic <z:hpo ids='HP_0001055'>erysipelas</z:hpo> of the right leg </plain></SENT>
<SENT sid="5" pm="."><plain>Both sites responded poorly to antibiotic therapy, offloading and debridement </plain></SENT>
<SENT sid="6" pm="."><plain>This skin <z:mpath ids='MPATH_70'>fistula</z:mpath> became <z:hpo ids='HP_0011010'>chronic</z:hpo> and some toes were at risk for minor <z:mpath ids='MPATH_686'>amputation</z:mpath> </plain></SENT>
<SENT sid="7" pm="."><plain>In view of the propensity for mTOR inhibitors to impair would healing, immunosuppression was switched back to <z:chebi fb="0" ids="4031">ciclosporin</z:chebi> </plain></SENT>
<SENT sid="8" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> wounds healed rapidly, but <z:e sem="disease" ids="C1519346" disease_type="Neoplastic Process" abbrv="">skin carcinogenesis</z:e> rose to former levels </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: This case impressively illustrates the clinical dilemma for mTOR inhibitor use where benefit in <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e> is counterbalanced by impairment in wound healing </plain></SENT>
<SENT sid="10" pm="."><plain>Changes in immunosuppressive regimens should thus be made on an individual basis with careful consideration of the relative risks </plain></SENT>
</text></document>